Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3084077 · 1 trial · 1 indication
An SAE is an adverse event that results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Single dose of placebo matching LY3084077 administered subcutaneously (SC). |
| LY3084077 | EXPERIMENTAL | Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Given as a SC injection. |
| LY3084077 | DRUG | Given as a SC injection. |
Inclusion Criteria: * Have normal blood pressure * Must be a healthy male or female who cannot become pregnant * Have a body mass index (BMI) of 18.5 to 40.0 kg/m\^2, inclusive, at screening Exclusion Criteria: * Have known allergies to fibroblast growth factor-21 (FGF21) analogues, glucagon-like...
LY3084077 is an investigational small molecule developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy participants. The specific disease or condition it is intended to treat has not been disclosed, and it remains in early clinical development.
LY3084077 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound in healthy participants.
LY3084077 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound has not been approved by the FDA and remains investigational.
LY3084077 has been evaluated in one completed Phase 1 trial, NCT01846702, titled A Study of LY3084077 in Healthy Participants. The trial enrolled 43 healthy volunteers in Singapore, was randomized, double-blind, and placebo-controlled, and included participants aged 21 years and older.
No. LY3084077 is an investigational small molecule in Phase 1 development and has not been approved by the FDA. Its only recorded clinical study, NCT01846702, has been completed.